“In conclusion, the anti-tumor activity of specific MKIs, such as regorafenib and sorafenib , is altered by the cellular redox status, suggesting that uncontrolled antioxidant intake during HCC treatment should be avoided or only endorsed to diminish chemotherapy-induced side effects, always under medical scrutiny.”